HYDERABAD, India
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced its unaudited consolidated financial results for the quarter ended September 30, 2013 under International Financial Reporting Standards (IFRS).
Key Highlights (Q2 FY14)
- Consolidated revenues at Rs. 33.6 billion, YoY growth of 17%.
- Revenues from the Global Generics (GG) segment at Rs. 26.5 billion, YoY growth of 32%. Growth driven by North America, Russia & other Emerging Markets.
- Revenues from the Pharmaceutical Services and Active Ingredients (PSAI) segment at Rs. 6.4 billion, YoY decline of 19%.
- Research & Development (R&D) expenses at Rs. 3.0 billion, 9% to revenues versus 6.1% to revenues as in Q2 FY13.
- Selling, general & administrative (SG&A) expenses at Rs. 9.7 billion, 29% to revenues versus 27.8% to revenues as in Q2 FY13.
- EBITDA at Rs. 9.5 billion, 28.3% to revenues versus 25.9% to revenues as in Q2 FY13.
- PAT at Rs. 6.9 billion, 20.6% to revenues versus 13.6% to revenues as in Q2 FY13.
- During the quarter, the company launched 19 new generic products, filed 13 new product registrations and filed 8 DMFs globally.
Note: Q2 FY 13 Income Statement considered is as submitted to the US SEC in the form 6K.
|
All figures in millions, except EPS |
All US dollar figures based on convenience translation rate of 1USD = Rs. 62.58 |
||||||||||||||
|
|
|||||||||||||||
|
Dr. Reddy’s Laboratories Limited and Subsidiaries |
|||||||||||||||
|
Unaudited Consolidated Income Statement |
|||||||||||||||
| Particulars | Q2 FY14 | Q2 FY13 | Growth % | ||||||||||||
| ($) |
(Rs.) |
% | ($) |
(Rs.) |
% | ||||||||||
| Revenues | 537 | 33,575 | 100.0 | 460 | 28,809 | 100.0 | 17 | ||||||||
| Cost of revenues | 225 | 14,106 | 42.0 | 219 | 13,708 | 47.6 | 3 | ||||||||
| Gross profit | 311 | 19,469 | 58.0 | 241 | 15,101 | 52.4 | 29 | ||||||||
| Operating Expenses | |||||||||||||||
| Selling, general & administrative expenses | 156 | 9,737 | 29.0 | 128 | 8,013 | 27.8 | 21 | ||||||||
| Research and development expenses | 48 | 3,009 | 9.0 | 28 | 1,759 | 6.1 | 71 | ||||||||
| Impairment loss on intangible assets | 8 | 507 | 1.8 | ||||||||||||
| Impairment loss on goodwill | 3 | 181 | 0.6 | ||||||||||||
| Other operating income | (10) | (637) | (1.9) | (6) | (397) | (1.4) | 60 | ||||||||
| Results from operating activities | 118 | 7,360 | 21.9 | 80 | 5,038 | 17.5 | 46 | ||||||||
| Net finance income | (5) | (291) | (0.9) | (6) | (371) | (1.3) | (22) | ||||||||
| Share of profit of equity accounted investees | (1) | (44) | (0.1) | (0) | (28) | (0.1) | 56 | ||||||||
| Profit before income tax | 123 | 7,695 | 22.9 | 87 | 5,437 | 18.9 | 42 | ||||||||
| Income tax expense | 13 | 792 | 2.4 | 24 | 1,512 | 5.2 | (48) | ||||||||
| Profit for the period | 110 | 6,903 | 20.6 | 63 | 3,925 | 13.6 | 76 | ||||||||
| Diluted Earnings per share | 0.65 | 40.5 | 0.37 | 23.1 | 75 | ||||||||||
|
EBITDA Computation: |
|||||||||||
| Particulars | Q2 FY14 | Q2 FY13 | |||||||||
| ($) |
(Rs.) |
($) |
(Rs.) |
||||||||
| Profit before income tax | 123 | 7,695 | 87 | 5,437 | |||||||
| Interest (income)/expense | 1 | 71 | (1) | (31) | |||||||
| Depreciation | 19 | 1,171 | 15 | 943 | |||||||
| Amortization | 9 | 562 | 7 | 433 | |||||||
| Impairment | – | – | 11 | 688 | |||||||
| EBITDA | 152 | 9,499 | 119 | 7,470 | |||||||
Segmental Analysis
Global Generics
Revenues from Global Generics segment for Q2 FY14 at Rs. 26.5 billion, YoY growth of 32% driven by North America, Russia and other Emerging Market territories.
- Revenues from North America for Q2 FY14 at Rs. 13.2 billion, YoY growth of 43%. Growth largely driven by:-
- Products launched in limited competition space namely finasteride 1mg, isotretinoin, zoledronic acid (5mg/100mL), zoledronic acid (4mg/5ml) etc during previous quarters post Sep. 2012 and 4 new products which were launched during the quarter – azacitidine, decitabine, donepezil 23mg, and divalproex ER tabs.
- Significant traction in market share of key existing products namely fondaparinux, omeprazole DR etc
- During the quarter, 4 ANDAs were filed. Cumulatively, 62 ANDAs are pending for approval with the USFDA of which 39 are Para IVs and we believe 9 have ‘First To File’ status.
- Revenues from Emerging Markets (which include Russia, CIS countries and RoW territories) for Q2 FY14 at Rs. 7.3 billion, YoY growth of 42%.
- Revenues from Russia at Rs. 4.6 billion, YoY growth of 44%. Growth was largely driven by volume uptake in the current quarter on account of seasonal impact.
- Revenues from CIS markets at Rs. 0.9 billion, YoY growth of 39%. Growth was largely driven by volume uptake of existing products and introduction of new products in Ukraine.
- Revenues from RoW territories stood at Rs. 1.8 billion, YoY growth of 36%.
- Revenues from India for Q2 FY14 at Rs. 4.2 billion, YoY growth of 8.5%.
- Resilient growth after considering trade disruptions and impact of the revised prices under new pharma pricing policy.
- Revenues from Europe for Q2 FY14 at Rs. 1.8 billion, remained flat YoY.
Pharmaceutical Services and Active Ingredients (PSAI)
- Revenues from PSAI for Q2 FY14 at Rs. 6.4 billion, YoY decline of 19%. Degrowth on the back of lower number of ‘launch molecules’ to our customers during the quarter.
- During the quarter, 8 DMFs were filed globally, including 1 in the US and 1 in Europe. The cumulative number of DMF filings as of September 30, 2013 is 590.
Income Statement Highlights:
- Gross profit margin at 58% in Q2 FY14 improved by nearly 560 basis points versus Q2 FY13. Gross profit margin for Global Generics and PSAI business segments are at 66.1% and 24.6% respectively.
GG gross margin improved primarily on account of higher contribution from new product launches in North America, where as PSAI gross margin declined, primarily on the back of lower number of launch molecules to our customers and relatively higher overheads during the quarter.
- SG&A expenses including amortization in Q2FY14 at Rs. 9.7 billion, YoY growth of 21%. The increase is primarily towards select brand building activities in the Emerging Market territories.
- R&D expenses stood at Rs. 3.0 billion, YoY growth of 71%; 9% to revenues in Q2 FY14 as compared to 6.1% to revenues in Q2 FY13.
- Net Finance income at Rs. 291 million in Q2 FY14 compared to the net finance income of Rs. 371 million in Q2 FY13. The change is on account of :
- Net incremental forex impact of Rs. 23 million
- Incremental net interest expense of Rs. 103 million
- EBITDA for Q2 FY14 at Rs. 9.5 billion, YoY growth of 27%; 28.3% to revenues.
- Profit after Tax in Q2 FY14 at Rs. 6.9 billion, YoY growth of 76%.
- Diluted earnings per share in Q2 FY 14 at Rs. 40.5
- Capital expenditure for Q2 FY14 is Rs. 3.8 billion.
|
All US dollar figures based on convenience translation rate of 1USD = Rs. 62.58 |
|||||||||
|
Appendix 1: Key Balance Sheet Items |
(in millions) |
||||||||
| Particulars | As on 30th Sep 2013 | As on 30th June 2013 | |||||||
| ($) |
(Rs.) |
($) |
(Rs.) |
||||||
| Cash and cash equivalents and current investments | 435 | 27,202 | 478 | 29,907 | |||||
| Trade receivables | 532 | 33,291 | 466 | 29,168 | |||||
| Inventories | 381 | 23,874 | 360 | 22,536 | |||||
| Property, plant and equipment | 679 | 42,477 | 629 | 39,393 | |||||
| Goodwill and Other Intangible assets | 244 | 15,274 | 236 | 14,787 | |||||
| Loans and borrowings (current & non-current) | 786 | 49,200 | 702 | 43,937 | |||||
| Trade payables | 173 | 10,828 | 161 | 10,076 | |||||
| Total Equity | 1,248 | 78,086 | 1,199 | 75,051 | |||||
|
Appendix 2: Revenue Mix by Segment |
(in millions) |
||||||||||||||
| Q2 FY14 | Q2 FY13 |
Growth |
|||||||||||||
| ($) |
(Rs.) |
% | ($) |
(Rs.) |
% | ||||||||||
| Global Generics | 424 | 26,548 | 79 | 321 | 20,103 | 70 | 32 | ||||||||
| North America | 13,244 | 50 | 9,270 | 46 | 43 | ||||||||||
| Europe | 1,761 | 6 | 1,777 | 9 | (1) | ||||||||||
| India | 4,207 | 16 | 3,879 | 19 | 8 | ||||||||||
| Russia & Other CIS | 5,516 | 21 | 3,841 | 19 | 44 | ||||||||||
| RoW | 1,820 | 7 | 1,336 | 7 | 36 | ||||||||||
| PSAI | 102 | 6,403 | 19 | 126 | 7,875 | 27 | (19) | ||||||||
| North America | 944 | 15 | 1,353 | 17 | (30) | ||||||||||
| Europe | 2,358 | 37 | 2,906 | 37 | (19) | ||||||||||
| India | 1,071 | 17 | 1,148 | 15 | (7) | ||||||||||
| RoW | 2,030 | 31 | |||||||||||||
